Impact of Two Different Types of Sedation on ICEB

Sponsor
Ankara City Hospital Bilkent (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05757063
Collaborator
(none)
70
1
2
5
13.9

Study Details

Study Description

Brief Summary

The QT interval is a measure of the combination of cardiac depolarization and repolarization as it encompasses both the QRS complex and the J-T interval. QT, QTc, QTd prolongation or shortening has been associated with ventricular arrhythmias . In order to define non-torsogenic drug-induced arrhythmias, the index of cardio-electrophysiological balance (iCEB), which is a new marker calculated with the QT/QRS formula, has been defined. In our study, we planned to evaluate the effects of dexmedetomidine and propofol on cardiac electrophysiology with all these parameters, especially the newly defined iCEB.

Condition or Disease Intervention/Treatment Phase
  • Other: Sedation with propofol
  • Other: sedation with dexmedetomidine
N/A

Detailed Description

Seventy patients who underwent operation under regional anesthesia and received intraoperative sedation will be included in the study. The patients will be divided into two groups, Group D (dexmedetomidine) and Group P (propofol). Sedative agent infusion will be started immediately after spinal anesthesia is administered. Preoperative ASA (American Society of Anesthesiologists) scores, demographic data, comorbidities and medications used will be recorded. Vitals and ECG prior to spinal anesthesia will be recorded. After that, spinal anesthesia will be applied and vitals and ECG will be recorded at 1, 5, 10, 15, 45 and 75 minutes. The sedation levels of the patients will be measured noninvasively by bispectral index (BIS) monitoring. Patients will be kept within the limits of light sedation. The maximum dose of 1.4 micrograms/kg/hour in the dexmedetomidine group (group D, n=35) and 4.5 milligrams/kg/hour in the propofol group (group P, n=35) will not be exceeded. The following parameters were set as the safety endpoint during sedation:

  • Respiratory rate ≤8

  • SpO2; 95

  • Heart rate; 40

  • Systolic blood pressure;80 At these endpoints, the patient's sedation dose will be reduced regardless of the BIS value.

During sedation, patients will be given 3 liters of nasal oxygen per minute, which can be increased according to need. Just before and 1st, 5th, 10th, 15th, 45th, 75th minutes after spinal anesthesia systolic arterial pressure, diastolic arterial pressure, mean arterial pressure,peak heart rate, oxygen saturation, bispectral index, QT time, QTc, QT distribution, Tpe, iCEB will be evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Effects of Two Different Sedation Protocols Used in Patients Undergoing Spinal Anesthesia on Cardiac Electrophysiology
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Propofol

Sedation procedure with propofol

Other: Sedation with propofol
After spinal anesthesia, patients will be sedated with propofol.

Active Comparator: Dexmedetomidine

Sedation procudure with dexmedetomidine

Other: sedation with dexmedetomidine
After spinal anesthesia, patients will be sedated with dexmedetomidine.

Outcome Measures

Primary Outcome Measures

  1. ICEBc [İntraoperative 10th minute]

    QTc/QRS formula

Secondary Outcome Measures

  1. ICEB [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    Index of cardio-electrophysiological balance (iCEB); calculated as QT distance divided by QRS duration (QT/ QRS), it will be calculated from the ECG.

  2. ICEBc [Baseline,İntraoperative 1th,5th,15th,30th,45th,75th minute]

    QTc/QRS formula

  3. QT [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    The investigator will assess the QT interval

  4. QTc [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    The investigator will assess the QTc interval

  5. QTd [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    maxQT-minQT

  6. Tpe [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    Tpeak-Tend

  7. Heart Rate [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    The investigator will assess the Heart Rate from ECG

  8. Bispektral index [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    bispectral index measurement

  9. non invaziv systolic blood pressure [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    non invasive systolic blood pressure measurement

  10. non invaziv diastolic blood pressure [Baseline,İntraoperative 1th,5th,10th,15th,30th,45th,75th minute]

    non invasive diastolic blood pressure measurement

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with ASA Ⅰ-Ⅱ ,

  • 18-80 years old, who will be operated under spinal anesthesia

Exclusion Criteria:
  • Hypersensitivity to the propofol,dexmedotimidine

  • preoperative QTc prolongation

  • preoperative heart disease

  • use of drugs that affect the QT interval

  • severe sinus bradycardia

  • preoperative electrolyte abnormalities

  • liver and kidney function abnormalities

  • non-sinus rhythm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ankara City Hospital Ankara Turkey

Sponsors and Collaborators

  • Ankara City Hospital Bilkent

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Burak NALBANT, assistant professor, Ankara City Hospital Bilkent
ClinicalTrials.gov Identifier:
NCT05757063
Other Study ID Numbers:
  • ICEB
First Posted:
Mar 7, 2023
Last Update Posted:
Mar 7, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 7, 2023